[144] Editas Medicine, Inc. SEC Filing

Rhea-AI Filing Summary

Editas Medicine (EDIT) Form 144 notice reports a proposed sale of 7,000 shares of Common Stock to be executed through ETrade on 09/03/2025 on Nasdaq with an aggregate market value of $19,110.00. The filing shows these shares were acquired on 09/02/2025 through restricted stock unit vesting (equity compensation), with 11,294 shares listed as acquired on that date. The filing also discloses a sale by Gilmore O'Neill of 15,192 shares on 06/03/2025 for gross proceeds of $26,195.57. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.

Positive

• Rule 144 compliance: The filer submitted a Form 144 to disclose the proposed sale as required.
• Source of shares disclosed: The shares to be sold were acquired via restricted stock unit vesting, clearly identified as equity compensation.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider notification of proposed sale following RSU vesting; transaction size appears immaterial to share count.

The Form 144 documents a planned disposition of newly vested equity (7,000 shares) executed via a broker on Nasdaq, with the shares acquired one day earlier by RSU vesting. This is a standard compliance filing under Rule 144 that notifies the market of an intended sale by an insider or person subject to resale restrictions. The filing also reports a prior sale of 15,192 shares by Gilmore O'Neill in June, with modest gross proceeds reported. There is no earnings, financing, or other corporate event disclosed in this filing that would by itself be material to equity valuation.

Corporate Governance Expert

TL;DR: Disclosure aligns with governance and insider trading rules; statement about absence of undisclosed material information is included.

The notice includes the seller's attestation that they are unaware of any material nonpublic information and references potential reliance on a Rule 10b5-1 trading plan if applicable. The filing documents acquisition by equity compensation (RSU vesting) and a near-term planned sale, which are common elements in insider equity management. No departures from standard disclosure or governance practice are evident from the submitted text.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETrade Financial Corporation 3 Edison Financial Alphareta GA 30005	7000	19110.00	89920164	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/02/2025	Restricted Stock Unit Vesting	Issuer			11294	09/02/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Gilmore O'Neill 11 Hurley Street Cambridge MA 02141	Common Stock	06/03/2025	15192	26195.57

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Editas Medicine (EDIT) Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 7,000 shares of Common Stock through ETrade on 09/03/2025 with aggregate market value $19,110.00.

How were the shares being sold acquired according to the filing?

The filing states the shares were acquired on 09/02/2025 through Restricted Stock Unit vesting and characterized as equity compensation.

Does the filing show any recent sales by the same person in the prior three months?

Yes. The filing reports that Gilmore O'Neill sold 15,192 shares on 06/03/2025 for gross proceeds of $26,195.57.

On which exchange is the proposed sale to be executed?

The proposed sale is to be executed on Nasdaq via ETrade Financial Corporation.

Does the filer attest to any information about undisclosed material facts?

Yes. The person for whose account the securities are to be sold represents by signing the notice that they do not know of any material adverse information regarding the issuer that has not been publicly disclosed.